Your browser doesn't support javascript.
loading
Improvement of FK506 production by synthetic biology approaches.
Fu, Li-Feng; Tao, Yang; Jin, Mei-Ying; Jiang, Hui.
Affiliation
  • Fu LF; Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd, Hangzhou, 310011, Zhejiang, China.
  • Tao Y; College of Life Sciences, Zhejiang University, 866 Yuhangtang Rd, Hangzhou, 310058, Zhejiang, China.
  • Jin MY; Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd, Hangzhou, 310011, Zhejiang, China.
  • Jiang H; College of Life Sciences, Zhejiang University, 866 Yuhangtang Rd, Hangzhou, 310058, Zhejiang, China. jianghuisioc@zju.edu.cn.
Biotechnol Lett ; 38(12): 2015-2021, 2016 Dec.
Article in En | MEDLINE | ID: mdl-27600954
ABSTRACT
Synthetic biology has been applied to direct improvement of valuable metabolite productions. Tacrolimus (FK506), a clinically used immunosuppressive agent isolated from many Streptomyces, is produced by fermentation in industry. Here we chose FK506 as an example to review recent progress in improving FK506 production, including enhancing transcription levels of biosynthetic genes, accelerating post-translational modification levels of biosynthetic enzymes, increasing activities of rate limiting enzymes, and rational supplement of limited precursors. FK506 production was increased from 25 % to sevenfold by these synthetic biology approaches.
Subject(s)
Key words
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Tacrolimus / Synthetic Biology Language: En Journal: Biotechnol Lett Year: 2016 Document type: Article Affiliation country: China
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Tacrolimus / Synthetic Biology Language: En Journal: Biotechnol Lett Year: 2016 Document type: Article Affiliation country: China